XTL Biopharmaceuticals Ltd (H2K2) — Financial Flexibility Index
XTL Biopharmaceuticals Ltd (H2K2) has a Financial Flexibility Index of -0.50x as of December 2024. Free cash flow of €-1.56 Million (operating CF €-1.62 Million minus capex €54.00K) represents -1% of total liabilities (€3.12 Million). Check XTL Biopharmaceuticals Ltd strategic asset allocation index to assess the company's strategic physical and investment asset allocation.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
XTL Biopharmaceuticals Ltd Financial Flexibility Index (2016–2024)
Historical Financial Flexibility Index trend for XTL Biopharmaceuticals Ltd across 9 annual periods. See XTL Biopharmaceuticals Ltd working capital to net assets to evaluate short-term liquidity relative to the company's equity base.
Annual Financial Flexibility Index for XTL Biopharmaceuticals Ltd (2016–2024)
Year-by-year free cash flow to debt coverage for XTL Biopharmaceuticals Ltd. For the full company profile including market capitalisation, see H2K2 stock market capitalisation.
| Year | Flexibility Index | Free Cash Flow (EUR) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2024 | -0.50x | €-1.56 Million | €-1.62 Million | €3.12 Million | ▲ +85.4% |
| 2023 | -3.43x | €-707.00K | €-707.00K | €206.00K | ▲ +28.8% |
| 2022 | -4.82x | €-901.00K | €-901.00K | €187.00K | ▼ -490.2% |
| 2021 | -0.82x | €-1.05 Million | €-1.05 Million | €1.28 Million | ▲ +75.6% |
| 2020 | -3.34x | €-849.00K | €-850.00K | €254.00K | ▲ +14.4% |
| 2019 | -3.91x | €-906.00K | €-908.00K | €232.00K | ▼ -21.4% |
| 2018 | -3.22x | €-814.00K | €-816.00K | €253.00K | ▼ -750.0% |
| 2017 | -0.38x | €-1.12 Million | €-1.12 Million | €2.97 Million | ▲ +92.5% |
| 2016 | -5.05x | €-1.67 Million | €-1.73 Million | €330.00K | — |